ScholarLens Back to search
2019•American Journal of Biomedical Science & ResearchOpen access

Direct Oral Anticoagulants for Paediatrics and Inherited Thrombophilia: Why Not?

Leonardo Di Gennaro

Open full text 0 citations

Abstract

Direct oral anticoagulants (DOAC) are indicated in the treatment and prevention of venous thromboembolism (VTE). However, the use of DOAC in paediatrics VTE, and in patients with inherited thrombophilia remains controversial due to the paucity of available data. However, the efficacy of DOAC may be suitable in children and in patients with thrombophilia. Randomized clinical trials, which are currently underway, should offer definitive insight into the efficacy and safety profiles of DOAC in these patient populations.

Open-access reader

About this research paper

What this paper is about

Direct oral anticoagulants (DOAC) are indicated in the treatment and prevention of venous thromboembolism (VTE). However, the use of DOAC in paediatrics VTE, and in patients with inherited thrombophilia remains controversial due to the paucity of available data. However, the efficacy of DOAC may be suitable in children and in patients with thrombophilia. Randomized clinical trials, which are currently underway, should offer definitive insight into the efficacy and safety profiles of DOAC in these patient populations.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Direct oral anticoagulants (DOAC) are indicated in the treatment and prevention of venous thromboembolism (VTE). However, the use of DOAC in paediatrics VTE, and in patients with inherited thrombophilia remains controversial due to the paucity of available data. However, the efficacy of DOAC may be suitable in children and in patients with thrombophilia. Randomized clinical trials, which are currently underway, should offer definitive insight into the efficacy and safety profiles of DOAC in these patient populations.

Key concepts: Thrombophilia, Medicine, Venous thromboembolism, Intensive care medicine, Randomized controlled trial, Pediatrics, Internal medicine, Thrombosis

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Direct Oral Anticoagulants for Paediatrics and Inherited Thrombophilia: Why Not? — Research Paper | ScholarLens